Data Platform Unifies Blood Cancer 'Omics' And Clinical Data to Accelerate Discovery
Scientists from St. Jude Children’s Research Hospital, the American Society for Hematology and the Munich Leukemia Laboratory launched the ASH HematOmics (ASHOP) platform, uniting genomics, transcriptomics and clinical data from 5,960 blood‑cancer patients. The open resource combines whole‑genome and whole‑transcriptome sequencing with outcomes across pediatric and adult leukemias, providing built‑in analysis tools that require no advanced coding. Initial use cases revealed previously hidden developmental subgroups in childhood B‑cell ALL and distinct molecular patterns in NPM1‑mutated AML. Findings were published in *Blood* on April 6, 2026.
Detecting Multiple Cancers and Other Diseases From a Single Blood Sample
UCLA researchers introduced MethylScan, a blood test that reads cell‑free DNA methylation to flag multiple cancers and liver diseases in a single assay. In a cohort of 1,061 participants the test achieved 98% specificity, detecting about 63% of cancers overall...
Pharmaceutical Executive Daily: Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics
Neurocrine Biosciences announced a $2.9 billion cash acquisition of Soleno Therapeutics, paying $53 per share—a 34% premium to Soleno’s closing price and 51% premium to its 30‑day VWAP. The deal brings Vykat XR, the only FDA‑approved therapy for hyperphagia in Prader‑Willi syndrome,...
Under-the-Skin Tepezza Comparable to Infused Version in Key Study, Amgen Says
Amgen announced that its subcutaneous on‑body injector version of Tepezza, called Tepezza OBI, met both primary and key secondary endpoints in a late‑stage trial, showing 77% of patients achieved a meaningful reduction in eye bulging. The efficacy was comparable to...
VDyne Secures FDA Nod to Start Pivotal Trial for Tricuspid Valve
VDyne received FDA approval for an investigational device exemption to launch its pivotal TRIVITA trial of a transcatheter tricuspid valve replacement system. The study will assess safety and efficacy in patients with severe symptomatic tricuspid regurgitation, a condition affecting roughly...
FDA Public Meeting: FDA-Led Patient-Focused Drug Development Meeting for Nonhealing Chronic Wounds - 08/25/2026
On August 25, 2026 the FDA will host a hybrid Patient‑Focused Drug Development meeting dedicated to non‑healing chronic wounds. The public session runs from 10 a.m. to 4:30 p.m. ET and combines a virtual webcast with an in‑person gathering at the White Oak Campus....
Proposed FDA Budget Sets Makary up to Boost US Biotech
The White House’s FY budget proposes a sizable increase for the FDA, positioning Dr. Robert Makary to spearhead regulatory reforms aimed at accelerating U.S. biotech development. The plan includes policy changes that would shorten clinical‑trial timelines, lower fees for early‑stage...
Immune Training Against Senescent Cells Reduces Tumor Growth
Here's my take on your paper: Cellular senescence or "zombie cell" events happen when a cell experiences too much genetic or epigenetic noise, caused by cellular damage (e.g. DNA breaks) or telomere erosion Your study of a Lewis Lung Carcinoma (LLC) mouse...
Academic Clinical Trials for Rapamycin to Answer Questions on Dosing for Anti-Aging Use
Researchers at UT Health San Antonio have launched a multi‑phase academic clinical trial to evaluate rapamycin’s biological effects in older adults. The program begins with a younger‑cohort benchmark study, then seeks the optimal dose that restores immune and metabolic markers...
Expanded MAGIC Toolkit Makes Genome-Wide Single-Cell Mosaic Analysis Possible in Drosophila
Cornell researchers have expanded the MAGIC (Mosaic Analysis by gRNA‑Induced Crossing‑over) toolkit to provide genome‑wide coverage across all Drosophila chromosomes, including the historically recalcitrant fourth chromosome. The new kit accelerates single‑cell mutant generation, cutting analysis time from months to weeks,...
Can Medicinal Cannabis Help Kids’ Autism, ADHD or Tourette’s? Here’s What We Know so Far
Interest in medicinal cannabis for children with autism, ADHD and Tourette's has grown, prompting the Australian Therapeutic Goods Administration to confirm that doctors are prescribing it for these conditions. While parents hope it could reduce reliance on stimulants, antidepressants and...
Global Cohort Data Bolster Confidence in Dolutegravir for Pediatric HIV Care
A new analysis presented at CROI 2026 used International Epidemiology Databases to Evaluate AIDS (IeDEA) data from Africa, Asia‑Pacific, and Latin America, covering over 90% of the world’s children with HIV. The study found that dolutegravir initiates modest early weight gain...
Tozorakimab Scores Double Win in Phase III COPD Trials
AstraZeneca announced that its IL‑33 monoclonal antibody tozorakimab achieved its primary endpoints in two Phase III COPD trials, Oberon and Titania. The drug significantly reduced the annual rate of moderate‑to‑severe exacerbations versus placebo across former and current smokers. AstraZeneca positions tozorakimab...
New Technique Identifies Proteins that Trigger Immune Responses in Transplants and Implants
Mayo Clinic researchers introduced a new method called the Ratio of Immunogenicity (ROI) to identify proteins that provoke strong immune responses. By measuring protein abundance and immune activation, the ROI ranks proteins from most to least immunogenic, revealing that mitochondrial...
Holland Foundation Looks to Expand Vision-Saving Transplants
The Holland Foundation for Sight Restoration is scaling its Cincinnati Protocol for ocular surface stem‑cell transplantation by establishing “centers of excellence” and expanding surgeon education. To date, five centers—from Cincinnati to UC Irvine, Virginia Eye Consultants, and Massachusetts Eye and...
Diabetes Drug Replicates Exercise Effects in Prostate Cancer Patients
How a Diabetes Drug May Echo the Benefits of Exercise in Prostate Cancer Care “From a clinical standpoint, seeing a metabolic signal that mirrors what we associate with intense exercise was striking… For patients whose treatments or symptoms limit physical activity,...
FDA Drug Info Rounds Video
The FDA’s Center for Drug Evaluation and Research has launched the Drug Info Rounds video series, a free on‑demand library that educates health‑care professionals on drug safety, regulatory processes, and compliance. The series covers topics such as MedWatch reporting, Medication...
Catalyst MedTech Establishes Full Access Neurology Solution for Brain PET Implementation in the U.S.
Catalyst MedTech announced the nationwide rollout of its Full Access Neurology solution, a bundled offering that enables health systems to deploy dedicated brain PET imaging without large capital outlays. The platform combines CareMiBrain‑powered scanners, quantification software, service and maintenance, and...
Pfizer's Late-Stage Lyme Vaccine Shows 73% Efficacy but Misses Primary Endpoint
Pfizer announced a late‑stage Lyme disease vaccine candidate that achieved 73.2% efficacy 28 days after the fourth dose, but the study missed its primary endpoint because of lower-than-expected case numbers. The vaccine, a monoclonal antibody developed with MassBiologics, will now...
CRISPR Therapeutics' One‑Time Gene Edit Cuts LDL by 49% in Early Trial
CRISPR Therapeutics reported that a one‑time CRISPR‑based therapy turned off the liver gene ANGPTL3, dropping LDL cholesterol by 49% and triglycerides by 55% in the highest‑dose cohort of a 15‑patient trial. The results, published in the New England Journal of...
Neurocrine to Acquire Soleno Therapeutics for $2.9 Billion in Cash
Neurocrine Pharmaceuticals has signed a definitive agreement to buy Soleno Therapeutics for $2.9 billion in cash, paying $53 per share—a 34% premium to Soleno’s April 2 close. The deal brings VYKAT XR, the only FDA‑approved drug for hyperphagia in Prader‑Willi syndrome, into Neurocrine’s...
BIO’s Comments for USTR Report Highlight Global Threats to Intellectual Property
The Biotechnology Innovation Organization (BIO) submitted comments to the USTR’s 2026 Special 301 Report urging stronger global enforcement of intellectual‑property (IP) rights for biotech. BIO argues that weak IP protections in markets such as Colombia, Russia and Brazil create barriers...
Other News to Note for April 6, 2026
Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that show pre‑clinical analgesic efficacy with fewer side effects. New hematopoietic stem‑cell research links chronic inflammation to early leukemic transformation, identifying inflammatory pathways as therapeutic targets. Infinimmune presented pre‑clinical data...
Regulatory Actions for April 6, 2026
BioWorld’s April 6, 2026 regulatory snapshot aggregates the day’s key FDA and global health authority actions across biopharma, medical technology, and diagnostics. The page links to data snapshots, special reports, infographics and trend analyses covering topics such as mRNA vaccine research, GLP‑1...
Amgen Seeks to Buoy Tepezza with Injectable Data in Face of Incoming Competition
Amgen announced that its injectable formulation of Tepezza achieved its primary endpoint in a Phase 3 trial for thyroid eye disease (TED). The data suggest the drug can be administered subcutaneously, offering a more convenient alternative to the current intravenous...
Machine Learning and Single-Cell Technology Combined to Drive High-Performance Cell Line Development
OneCyte and Kemp Proteins have formed a strategic partnership that fuses OneCyte’s high‑throughput single‑cell cloning platform with Kemp’s machine‑learning‑driven protein design system, PROTiQ. The combined workflow uses in‑silico sequence evaluation to flag developability risks, then rapidly screens thousands of clones...
Anthropic Pays $400M for Biotech; Praxis Epilepsy Drug Hits in Phase 1/2 Trial
San Francisco AI firm Anthropic announced a $400 million acquisition of stealth biotech Coefficient Bio, signaling its push into drug discovery. The purchase aims to integrate Anthropic’s large‑language‑model capabilities with biotech research pipelines. In parallel, Praxis Therapeutics disclosed encouraging Phase 1/2 data...
Takeda Ends Partnership with Denali Amid Restructuring
Takeda announced the termination of its eight‑year partnership with Denali Therapeutics, returning full rights to the experimental drug DNL593 ahead of its upcoming Phase I trial. The move is part of Takeda's broader restructuring aimed at streamlining its portfolio and...
From Prenatal DNA Test to $4B Cancer Detection Promise
1 in 11 babies born in America this year will be screened by a genetic test that didn't exist a decade ago. Biotech startup @BillionToOneInc turned a simple but radical idea—detecting rare fragments of fetal DNA in a mother's blood—into one...
Resveratrol Alters Sperm Epigenetics, Boosts Offspring Metabolism
CRAZY IF TRUE PAPER: A new study in mice reports that resveratrol intake by old male mice (or directly treating their sperm) changes the metabolism of embryos & pups, "potentially through alterations in sperm telomere length and epigenetic modifications"...
African Patients and Trialists Largely Left Out of CV Research
A new study reveals that African populations are dramatically underrepresented in cardiovascular clinical trials, with less than 4 % of 2,472 randomized controlled trials (RCTs) conducted exclusively in Africa and only 0.6 % appearing in top cardiology journals. Lead author Bamba Gaye...
Meta-Analyses Reveal Psychedelics Boost Brain Circuits
Two systematic, meta-analyses on psychedelic drugs today Brain Circuit Function @NatureMedicine https://t.co/nBmjreYEXU Depression @NatMentHealth https://t.co/zJR06AsC0Z https://t.co/qpWdjzBR4D
Cell Senescence Drives Cancer Risk, Yet Can Be Modulated
Cell senescence and how it predisposes to cancer, no less how we may be able to modulate it. An outstanding @CellCellPress review https://t.co/bmAXOS1Ybz
STAT+: Pharmalittle: We’re Reading About an FDA Delay Forcing a Biotech to Close, a Neurocrine Deal, and More
In February, Kezar Life Sciences secured an FDA agreement for a clinical trial on autoimmune hepatitis, but the meeting was cancelled four months late, prompting the biotech to begin winding down. Meanwhile, U.S. physicians are increasingly prescribing oral GLP‑1 weight‑loss...
Rethinking eCOA: Why Earlier Input by Data Managers Is Needed
Electronic clinical outcome assessment (eCOA) is a mature technology, yet its adoption lags behind other digital trial tools. The traditional siloed approach forces data managers to engage only after data collection, inflating costs and extending timelines. Involving data managers early...
Engineered Antibodies Pry Apart The Most Difficult Viruses
Researchers have engineered a bifunctional antibody fragment that simultaneously blocks Marburg virus attachment and neutralizes the exposed receptor‑binding site after the virus undergoes its conformational change. By mimicking the host cell receptor, the antibody tightly binds the viral protein, shutting...
Myeloma Survival Breakthrough: Two Decades After Dalton’s Wish
I remember interviewing Bill Dalton in 2005 about new developments in myeloma and how he wished for new regimens to take OS out beyond 3-4 yrs. Two decades on we've hit jackpot...
Neurocrine to Acquire Prader-Will Drug in $2.9B Soleno Buyout
Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, securing the rare‑disease drug Vykat XR. Vykat generated $190 million in 2025 sales, including $92 million in the fourth quarter, but recent safety concerns and a slowdown in new patient starts have clouded its...
‘Over and Above’ Responses Seen with Envudeucitinib for Plaque Psoriasis
Phase 3 ONWARD 1 and ONWARD 2 trials showed that envudeucitinib, an oral next‑generation TYK2 inhibitor, produced rapid and deep skin clearance in moderate‑to‑severe plaque psoriasis. At week 16, 76.5% and 70.4% of patients achieved PASI‑75, with rates climbing above 78% by week 24, and...
CuraTeQ Biologics Gets ‘Positive’ Results in Phase Study of Omalizumab
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, announced positive top‑line results from its Phase 3 trial of BP11, a biosimilar to omalizumab (Xolair). The study enrolled 608 patients across 80 sites in seven European countries and India, meeting all primary endpoints...
From Noncovalent Fragment to (Non)covalent Leads Against PLPro
Researchers at Vanderbilt have leveraged a protein‑observed NMR fragment screen to revive interest in SARS‑CoV‑2 papain‑like protease (PLPro), an essential viral enzyme with few existing inhibitors. From 13,824 fragments, 77 hits were confirmed, leading to a non‑covalent series that progressed...
STAT+: Stealth Biotech Stipple Bets on Secretive ADCs
Stealth biotech Stipple is quietly advancing secretive antibody‑drug conjugates (ADCs) as the market races toward targeted cancer therapies. A recent four‑month FDA review delay forced a cash‑strapped small biotech to shut down, underscoring the existential risk of regulatory setbacks for...
Quemliclustat
Quemliclustat (AB680) is a highly potent (5 pM) selective CD73 inhibitor that completed a Phase I trial in healthy volunteers, demonstrating a pharmacokinetic profile suitable for biweekly intravenous dosing. Early clinical data showed promising activity, prompting a successful Phase II study in pancreatic...
FDA Grants IND and Fast Track for Cartography Bio’s T‑Cell Engager CBI‑1214 in Colorectal Cancer
Cartography Bio secured FDA approval of an investigational new drug application and fast‑track designation for its T‑cell engager CBI‑1214, aimed at colorectal cancer. The clearance lets the company launch a Phase 1 study, marking a milestone for cellular immunotherapy in a...
Module 3, Section 2: Quality Not Quantity
The article emphasizes a shift in high‑throughput screening toward curated, high‑quality compound libraries rather than sheer volume. It cites literature on global pharmacological mapping that shows enhanced hit relevance when nonspecific inhibitors are minimized. Phenotypic versus target‑based discovery is highlighted...
Promoting OSKM Therapy with MYC Is Borderline Criminal
The fact that some scientists are still touting OSKM as a therapy, which includes the cancer-causing oncogene MYC, is borderline criminal
FDA Backs Permanent Re‑authorization of Pediatric PRV Program
FDA calls to permanently re-authorize the rare pediatric disease PRV program in Friday's 2027 budget plan -- far cry from the FDA that complained to the GAO about PRVs as distracting from their public health priorities https://t.co/i79F7X1ECw
Pharma Pipeline Stalls for First Time in Decades: Citeline
The Citeline Pharma R&D report shows the first decline in investigational drug candidates since the mid‑1990s, with the pipeline falling 3.92% to 22,940 assets at the start of 2026. While a methodological tweak may have softened the drop, the contraction...
FDA Delay Shuts Down Small Biotech in Four Months
How a four-month FDA delay forced a small biotech company to close its doors https://t.co/6vMGJM5SjH
Rust Prototype Brings Terminal Transcriptome Browser to Life
Almost done with a prototype Rust port of my Scriptoscope python app for transcriptome browsing, all in-terminal. Inspired by @Psy_Fer_'s ask to read from the holy books of Rust. https://t.co/OPr8rjFKj6